Poliovirus vaccine, live, oral, trivalent

Poliovirus vaccine, live, oral, trivalent, is a live virus vaccine that induces protective antibodies, reducing intestinal and pharyngeal excretion of poliovirus. OPV administration simulates natural infection, inducing active mucosal and systemic immunity against poliovirus types 1, 2, and 3. 

Two types of trivalent poliovirus vaccines are currently licensed for distribution in the United States an enhanced inactivated vaccine (IPV) and a live attenuated, oral vaccine (OPV). IPV is the recommended vaccine for the primary series and booster dose for children in the United States, whereas OPV is recommended in areas of the world that have circulating poliovirus. 

An inactivated trivalent vaccine developed by Jonas Salk was licensed for use in 1955. In 1987, an enhanced-potency inactivated poho vaccine (IPV) was introduced, and it has replaced the original inactivated vaccine. A live attenuated oral polio vaccine (OPV) was developed by Albert Sabin in 1962. OPV was the primary immunizing agent for poliovirus infection. Widespread OPV use is responsible for eradication of wild-type polio in most of the world. However, with no poliovirus circulation in the United States for years, IPV is the recommended vaccine for the primary series and booster dose for children. OPV will continue to be used in the areas of the world that have circulating pohovirus. The CEX7 maintains a stockpile of OPV to be used only in case of an outbreak. ... 

---